Two Sigma Investments, LP Taysha Gene Therapies, Inc. Transaction History

Two Sigma Investments, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.43 - $3.25 $22,102 - $50,232	-15,456 Reduced 11.28%	121,517 $348,000
Q4 2023 Feb 14, 2024	BUY	$1.33 - $2.88 $182,174 - $394,482	136,973 New	136,973 $242,000
Q3 2022 Nov 14, 2022	SELL	$1.76 - $4.94 $42,708 - $119,874	-24,266 Reduced 35.87%	43,378 $84,000
Q2 2022 Aug 15, 2022	SELL	$2.47 - $6.77 $282,232 - $773,567	-114,264 Reduced 62.81%	67,644 $252,000
Q1 2022 May 16, 2022	BUY	$5.22 - $11.86 $588,184 - $1.34 Million	112,679 Added 162.76%	181,908 $1.19 Million
Q4 2021 Feb 14, 2022	BUY	$11.43 - $19.2 $791,287 - $1.33 Million	69,229 New	69,229 $807,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $103M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.